AN2 Therapeutics reprices stock options to $3.91; original exercise price applies if exercised before Premium End Date

AN2 Therapeutics, Inc.

Board approved repricing of all outstanding options to $3.91 per share (closing price on March 19, 2026).
Repriced options subject to original exercise price if exercised before Premium End Date (Sept 19, 2027, change in control, or death/disability).
Named executive officers hold 1,106,764 total Eligible Options with original exercise prices ranging from $6.60 to $17.88.
CEO Eric Easom holds 742,649 repriced options; CFO Lucy Day holds 221,965; CLO/COO Joshua Eizen holds 142,150.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.